Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 16/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1807441 | 0.94 | DRD4 (0.44) | DRD4SIGMAR1GRM2KCNH2NR1I2 | |
| SCHEMBL1807203 | 0.93 | DRD4 (0.45) | DRD4SIGMAR1GRM2KCNH2KDM4E | |
| SCHEMBL1812609 | 0.90 | DRD4 (0.39) | DRD4SIGMAR1GRM2KCNH2KDM4E | |
| SCHEMBL1807782 | 0.90 | DRD4 (0.43) | DRD4SIGMAR1GRM2KCNH2KDM4E | |
| SCHEMBL1811133 | 0.90 | CCR3 (0.47) | DRD4SIGMAR1GRM2KCNH2NR1I2 | |
| SCHEMBL1807255 | 0.89 | CCR3 (0.40) | DRD4SIGMAR1GRM2KCNH2NR1I2 | |
| SCHEMBL1809878 | 0.88 | DRD4 (0.45) | DRD4SIGMAR1KDM4ERAB9A | |
| SCHEMBL1812062 | 0.87 | DRD4 (0.47) | DRD4SIGMAR1 | |
| SCHEMBL1808083 | 0.85 | DRD4 (0.39) | DRD4SIGMAR1GRM2KCNH2KDM4E | |
| SCHEMBL1807518 | 0.85 | DRD4 (0.41) | DRD4SIGMAR1GRM2KCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | DRD4 768/4885SIGMAR1 808/4885GRM2 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.